{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:11:56Z","timestamp":1788336716586,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007265","name":"Boston University Chobanian & Avedisian School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019921","name":"National Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pupt.2025.102374","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:12:59Z","timestamp":1749654779000},"page":"102374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease"],"prefix":"10.1016","volume":"90","author":[{"given":"Daniel","family":"Connelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Delahanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Ackerbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Klings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-3766","authenticated-orcid":false,"given":"Justin K.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4187\/respcare.03927","article-title":"Inhaled therapies for pulmonary hypertension","volume":"60","author":"Hill","year":"2015","journal-title":"Respir. Care"},{"issue":"10","key":"10.1016\/j.pupt.2025.102374_bib2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/1060028015595642","article-title":"Noninferiority of inhaled epoprostenol to inhaled nitric oxide for the treatment of ARDS","volume":"49","author":"Ammar","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.pupt.2025.102374_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/0885066620906800","article-title":"Comparison of fixed-dose inhaled epoprostenol and inhaled nitric oxide for acute respiratory distress syndrome in critically ill adults","volume":"36","author":"Buckley","year":"2021","journal-title":"J. Intensive Care Med."},{"issue":"8","key":"10.1016\/j.pupt.2025.102374_bib4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4187\/respcare.03424","article-title":"Inhaled epoprostenol in ARDS","volume":"59","author":"Modrykamien","year":"2014","journal-title":"Respir. Care"},{"issue":"10","key":"10.1016\/j.pupt.2025.102374_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/10600280211069182","article-title":"Evaluation of continuous inhaled epoprostenol in the treatment of acute respiratory distress syndrome, including patients with SARS-CoV-2 infection","volume":"56","author":"Niss","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1753465815599345","article-title":"The role of inhaled prostacyclin in treating acute respiratory distress syndrome","volume":"9","author":"Searcy","year":"2015","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TA.0b013e318258431e","article-title":"Inhaled epoprostenol improves oxygenation in severe hypoxemia","volume":"73","author":"Tabrizi","year":"2012","journal-title":"J. Trauma Acute Care Surg."},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcrc.2013.03.006","article-title":"Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients","volume":"28","author":"Torbic","year":"2013","journal-title":"J. Crit. Care"},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.5603\/CJ.a2020.0164","article-title":"Antiplatelet effects of prostacyclin analogues: which one to choose in case of thrombosis or bleeding?","volume":"28","author":"Rogula","year":"2021","journal-title":"Cardiol. J."},{"issue":"4","key":"10.1016\/j.pupt.2025.102374_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1513\/pats.200705-054VS","article-title":"Regulation of heterotrimeric G protein signaling in airway smooth muscle","volume":"5","author":"Penn","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1983.tb01467.x","article-title":"Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects","volume":"15","author":"Shepherd","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.pupt.2025.102374_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/156652411800615144","article-title":"Prostacyclin receptor regulation--from transcription to trafficking","volume":"11","author":"Midgett","year":"2011","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/08998280.2019.1668668","article-title":"Inhaled epoprostenol utilization pattern after implementation of an administration policy","volume":"33","author":"Collier","year":"2020","journal-title":"Proc. - Bayl. Univ. Med. Cent."},{"key":"10.1016\/j.pupt.2025.102374_bib15","series-title":"Pharmacol Noninvasive Vent [Internet]","first-page":"127","article-title":"Inhaled epoprostenol pharmacology therapy in pulmonary arterial hypertension during noninvasive mechanical ventilation","author":"Obaidan","year":"2023"},{"issue":"10","key":"10.1016\/j.pupt.2025.102374_bib16","article-title":"Unexpected interruptions in the inhaled epoprostenol delivery system: incidence of adverse sequelae and therapeutic consequences in critically ill patients","volume":"3","author":"Block","year":"2021","journal-title":"Crit. Care Explor."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/pharmaceutics11060281","article-title":"Epoprostenol delivered via high flow nasal cannula for ICU subjects with severe hypoxemia comorbid with pulmonary hypertension or right heart dysfunction","volume":"11","author":"Li","year":"2019","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.pupt.2025.102374_bib18","article-title":"Use of epoprostenol in the treatment of pulmonary arterial hypertension","volume":"13","author":"Mohammadi","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2125.2012.04301.x","article-title":"Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects","volume":"74","author":"Nicolas","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bph.14512","article-title":"Inhaled nitric oxide","volume":"176","author":"Yu","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pupt.2025.102374_bib21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/00000542-199910000-00030","article-title":"Inhaled nitric oxide: basic biology and clinical applications","volume":"91","author":"Steudel","year":"1999","journal-title":"Anesthesiology"},{"issue":"8","key":"10.1016\/j.pupt.2025.102374_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2362.1993.tb00797.x","article-title":"Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome","volume":"23","author":"Gerlach","year":"1993","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.pupt.2025.102374_bib23","series-title":"Nitric Oxide. StatPearls [Internet]","author":"Witek","year":"2024"},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00003246-199801000-00011","article-title":"Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group","volume":"26","author":"Dellinger","year":"1998","journal-title":"Crit. Care Med."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4187\/respcare.08856","article-title":"Inhaled nitric oxide delivery systems for mechanically ventilated and nonintubated patients: a review","volume":"66","author":"Gianni","year":"2021","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/59.1.5","article-title":"The toxicology of inhaled nitric oxide","volume":"59","author":"Weinberger","year":"2001","journal-title":"Toxicol. Sci."},{"issue":"3 Pt 1","key":"10.1016\/j.pupt.2025.102374_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/peds.101.3.325","article-title":"Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO\/PPHN Study Group","volume":"101","author":"Davidson","year":"1998","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1172\/JCI200112761","article-title":"Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery","volume":"108","author":"Cannon","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/bja\/76.5.652","article-title":"Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers","volume":"76","author":"Young","year":"1996","journal-title":"Br. J. Anaesth."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/2045893217719250","article-title":"Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension","volume":"7","author":"Kingman","year":"2017","journal-title":"Pulm. Circ."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib31","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1378\/chest.14-3161","article-title":"The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis","volume":"147","author":"Fuller","year":"2015","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1060028019888853","article-title":"Effectiveness, safety, and economic comparison of inhaled epoprostenol brands, flolan and Veletri, in acute respiratory distress syndrome","volume":"54","author":"Hawn","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0885066606287045","article-title":"Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome","volume":"21","author":"Cepkova","year":"2006","journal-title":"J. Intensive Care Med."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.chest.2022.08.001","article-title":"Inhaled nitric oxide vs epoprostenol during acute respiratory failure: an observational target trial emulation","volume":"162","author":"Bosch","year":"2022","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.pupt.2025.102374_bib35","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin Definition","volume":"307","author":"ARDS Definition Task Force","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1164\/rccm.202303-0558WS","article-title":"A new global definition of acute respiratory distress syndrome","volume":"209","author":"Matthay","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1213\/ANE.0b013e3181e9c356","article-title":"Special article: rescue therapies for acute hypoxemic respiratory failure","volume":"111","author":"Liu","year":"2010","journal-title":"Anesth. Analg."},{"issue":"10","key":"10.1016\/j.pupt.2025.102374_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4187\/respcare.01366","article-title":"Approaches to refractory hypoxemia in acute respiratory distress syndrome: current understanding, evidence, and debate","volume":"56","author":"Collins","year":"2011","journal-title":"Respir. Care"},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/10600280231194539","article-title":"A narrative review on the administration of inhaled prostaglandins in critically ill adult patients with acute respiratory distress syndrome","volume":"58","author":"Ware","year":"2024","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1513\/AnnalsATS.201606-438OC","article-title":"Adjuvants to mechanical ventilation for acute respiratory failure. Adoption, de-adoption, and factors associated with selection","volume":"14","author":"Munshi","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270646","article-title":"Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19","volume":"17","author":"Poonam","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pupt.2025.102374_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/08850666221081757","article-title":"Predicting impact of prone position on oxygenation in mechanically ventilated patients with COVID-19","volume":"37","author":"Bell","year":"2022","journal-title":"J. Intensive Care Med."},{"issue":"12","key":"10.1016\/j.pupt.2025.102374_bib43","article-title":"Effects of inhaled epoprostenol and prone positioning in intubated coronavirus disease 2019 patients with refractory hypoxemia","volume":"2","author":"Li","year":"2020","journal-title":"Crit. Care Explor."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0885066620976525","article-title":"Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19","volume":"36","author":"Sonti","year":"2021","journal-title":"J. Intensive Care Med."},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2025.102374_bib45","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ajhp\/zxac192","article-title":"Comparison of 2 different inhaled epoprostenol dosing strategies for acute respiratory distress syndrome in critically ill adults: weight-based vs fixed-dose administration","volume":"80","author":"Buckley","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"8","key":"10.1016\/j.pupt.2025.102374_bib46","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.4187\/respcare.05268","article-title":"Severity of hypoxemia and other factors that influence the response to aerosolized prostacyclin in ARDS","volume":"62","author":"Kallet","year":"2017","journal-title":"Respir. Care"},{"issue":"8","key":"10.1016\/j.pupt.2025.102374_bib47","article-title":"A comparison of inhaled epoprostenol in patients with acute respiratory distress syndrome and COVID-19-associated acute respiratory distress syndrome","volume":"14","author":"Robinson","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00003246-200101000-00015","article-title":"Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response","volume":"29","author":"Domenighetti","year":"2001","journal-title":"Crit. Care Med."},{"issue":"3 Pt 1","key":"10.1016\/j.pupt.2025.102374_bib49","first-page":"724","article-title":"Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis","volume":"151","author":"Walmrath","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/21548331.2022.2047310","article-title":"Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019","volume":"50","author":"Kataria","year":"1995","journal-title":"Hosp. Pract."},{"issue":"12","key":"10.1016\/j.pupt.2025.102374_bib51","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1177\/1060028018782209","article-title":"Inhaled epoprostenol through noninvasive routes of ventilator support systems","volume":"52","author":"Ammar","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.chstcc.2023.100019","article-title":"Use of inhaled epoprostenol in patients with COVID-19 receiving humidified, high-flow nasal oxygen is associated with progressive respiratory failure","volume":"1","author":"Michelson","year":"2023","journal-title":"CHEST Crit. Care."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.36518\/2689-0216.1563","article-title":"Impact of inhaled epoprostenol in patients on COVID-19 acute respiratory distress syndrome (ARDS)","volume":"4","author":"Nguyen","year":"2023","journal-title":"HCA Healthc. J. Med."},{"key":"10.1016\/j.pupt.2025.102374_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.153989","article-title":"Letter to the Editor: \u201cUse of inhaled epoprostenol with high flow nasal oxygen in non-intubated patients with severe COVID-19.\u201d","volume":"69","author":"Chiles","year":"2022","journal-title":"J. Crit. Care"},{"issue":"8","key":"10.1016\/j.pupt.2025.102374_bib55","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4187\/respcare.02939","article-title":"Predictors of outcome in 216 subjects with ARDS treated with inhaled epoprostenol","volume":"59","author":"Pacheco","year":"2014","journal-title":"Respir. Care"},{"key":"10.1016\/j.pupt.2025.102374_bib56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ajem.2022.06.009","article-title":"A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department","volume":"58","author":"Toomey","year":"2022","journal-title":"Am. J. Emerg. Med."},{"issue":"12","key":"10.1016\/j.pupt.2025.102374_bib57","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1513\/AnnalsATS.201612-1042OC","article-title":"Management of acute respiratory distress syndrome and refractory hypoxemia. A multicenter observational study","volume":"14","author":"Duan","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0971-9784.173030","article-title":"Management of refractory hypoxemia","volume":"19","author":"Mehta","year":"2016","journal-title":"Ann. Card Anaesth."},{"issue":"38","key":"10.1016\/j.pupt.2025.102374_bib59","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/2045-8932.109916","article-title":"Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension","volume":"3","author":"Preston","year":"2013","journal-title":"Pulm. Circ."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib62","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3390\/jcm13030869","article-title":"Approach to decompensated right heart failure in the acute setting","volume":"13","author":"Levitt","year":"2024","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s13054-014-0523-z","article-title":"Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness","volume":"18","author":"Muzevich","year":"2014","journal-title":"Crit. Care"},{"issue":"4","key":"10.1016\/j.pupt.2025.102374_bib64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0885066621993041","article-title":"Critical care of patients with cardiopulmonary complications of sarcoidosis","volume":"37","author":"Lui","year":"2022","journal-title":"J. Intensive Care Med."},{"issue":"5","key":"10.1016\/j.pupt.2025.102374_bib65","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1513\/AnnalsATS.201312-446FR","article-title":"Management of acute right ventricular failure in the intensive care unit","volume":"11","author":"Ventetuolo","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"17","key":"10.1016\/j.pupt.2025.102374_bib66","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/CIRCULATIONAHA.122.062464","article-title":"Inhaled epoprostenol compared with nitric oxide for right ventricular support after major cardiac surgery","volume":"148","author":"Ghadimi","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2025.102374_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.667328","article-title":"Post-operative right ventricular failure after cardiac surgery: a cohort study","volume":"8","author":"Levy","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib68","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mtc.2003.107","article-title":"Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery","volume":"125","author":"Hach\u00e9","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340310790231671","article-title":"Pulmonary hypertension in cardiac surgery","volume":"6","author":"Denault","year":"2010","journal-title":"Curr. Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2025.102374_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1060028015608865","article-title":"A comparison of inhaled nitric oxide versus inhaled epoprostenol for acute pulmonary hypertension following cardiac surgery","volume":"50","author":"McGinn","year":"2016","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11748-016-0724-2","article-title":"A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy","volume":"65","author":"Abe","year":"2017","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0886-0440.2005.200383w.x","article-title":"Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement","volume":"20","author":"Fattouch","year":"2005","journal-title":"J. Card. Surg."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2459\/01.JCM.0000203850.97890.fe","article-title":"Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study","volume":"7","author":"Fattouch","year":"2006","journal-title":"J. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.pupt.2025.102374_bib74","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jtcvs.2009.04.063","article-title":"A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients","volume":"138","author":"Khan","year":"2009","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"7","key":"10.1016\/j.pupt.2025.102374_bib75","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1053-0770(96)80047-4","article-title":"Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study","volume":"10","author":"Haraldsson","year":"1996","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1213\/ANE.0000000000006192","article-title":"Pulmonary vasodilator response of combined inhaled epoprostenol and inhaled milrinone in cardiac surgical patients","volume":"136","author":"Elmi-Sarabi","year":"2023","journal-title":"Anesth. Analg."},{"issue":"2","key":"10.1016\/j.pupt.2025.102374_bib77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/jcm9020464","article-title":"The clinical impact of flow titration on epoprostenol delivery via high flow nasal cannula for ICU patients with pulmonary hypertension or right ventricular dysfunction: a retrospective cohort comparison study","volume":"9","author":"Li","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.pupt.2025.102374_bib78","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03017361","article-title":"Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit","volume":"48","author":"Hach\u00e9","year":"2001","journal-title":"Can. J. Anaesth."},{"issue":"4","key":"10.1016\/j.pupt.2025.102374_bib79","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jtcvs.2003.11.035","article-title":"Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery","volume":"127","author":"De Wet","year":"2004","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.pupt.2025.102374_bib80","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11897-023-00601-5","article-title":"Management of acute right ventricular failure","volume":"20","author":"Asakage","year":"2023","journal-title":"Curr. Heart Fail. Rep."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553925000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:01:30Z","timestamp":1756900890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553925000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":80,"alternative-id":["S1094553925000318"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102374","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2025.102374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102374"}}